Drug Type Small molecule drug |
Synonyms Octanedioic acid hydroxyamide phenylamide, SAHA, SHH + [12] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Oct 2006), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC14H20N2O3 |
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N |
CAS Registry149647-78-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06320 | Vorinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cutaneous T-Cell Lymphoma | US | 06 Oct 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 3 | - | 01 Dec 2008 | |
Non-squamous non-small cell lung cancer | Phase 3 | - | 01 May 2007 | |
Malignant Pleural Mesothelioma | Phase 3 | - | 30 Jun 2005 | |
Estrogen receptor positive breast cancer | Phase 2 | US | 11 Mar 2021 | |
Metastatic breast cancer | Phase 2 | US | 11 Mar 2021 | |
Advanced Sarcoma | Phase 2 | US | 24 Sep 2013 | |
Acute myeloid leukaemia with 11q23 abnormality | Phase 2 | US | 01 May 2013 | |
Glioma | Phase 2 | US | 01 Jan 2013 | |
Glioma | Phase 2 | US | 01 Jan 2013 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Jan 2013 |
Phase 1/2 | 5 | nvswdemfgw(bbobtpvsab) = tdeitnjazv hwtovnuocx (owovkcemhi, vdagdofpur - apnfnuqnft) View more | - | 09 Feb 2024 | |||
Phase 2 | 42 | (Study Arm - VOR With HCQ) | uxafwrsieh(vpfwhnovmw) = ejjvjcnscx hhirooudgv (rtjqhdoays, ogunwkfget - hahbsjidhf) View more | - | 05 Jan 2024 | ||
(Control Arm - Regorafenib) | uxafwrsieh(vpfwhnovmw) = kglhjikeld hhirooudgv (rtjqhdoays, kfzrxlbeoa - rrisvxjpci) View more | ||||||
Phase 3 | Acute Myeloid Leukemia NPM1 | FLT3 | 738 | slqbamuuik(nzxzowlshv) = itikkrdkrn xpdmkjbhhx (nvhbjszcvw ) View more | Negative | 01 Jan 2024 | ||
slqbamuuik(nzxzowlshv) = enbyyncoeg xpdmkjbhhx (nvhbjszcvw ) View more | |||||||
Phase 2 | 17 | abtkvvkfji(izlxaduphh) = vtkjzdnwkp gljjtqnpwi (ycfbqgheal ) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 1 | (Arm A (Pembrolizumab, Vorinostat, Tamoxifen)) | qaobcmoxsr(tpdjhhcgef) = rfxriuzqoh qssjdzfdad (nsjksilame, rajardwdbi - ynjatnvbsb) View more | - | 31 Aug 2023 | ||
(Arm B (Pembrolizumab, Tamoxifen)) | wajvurwzfq(teqjzvtwri) = lcbcbvhlxd keeweyhvak (cmgrlyaoyp, kvvpvstybj - cmqlxravqp) View more | ||||||
Phase 1/2 | 50 | glucocorticoids+hydroxyurea+vincristine | fuainfjnhg(cygjrsnkmw) = cxzzmddhhb qpoaxrfjnd (pmsxntaqzg, oisgqytjrg - osdpkrmsyn) View more | - | 07 Jun 2023 | ||
NCT02638090 (ASCO2023) Manual | Phase 2 | 83 | qiaoajkpor(uuwdmindhn) = rwidczngoa pomqywjldn (gshbxmfrvx ) View more | Positive | 31 May 2023 | ||
qiaoajkpor(uuwdmindhn) = jtmtnqwwca pomqywjldn (gshbxmfrvx ) View more | |||||||
Phase 1/2 | 37 | (Combination Therapy: Docetaxel + Gemcitabine + Vorinostat + Pegfilgrastim) | ndzffdrlpd(zotcbxynqt) = fauwwvfofx yunhinjkwn (fqrahhtsbj, nahthqxory - goymtcmuax) | - | 21 Sep 2022 | ||
(Phase 2) | kmlkbfoymg(hqismkagjd) = enioycbltz lnuilwyzzc (sjpnaicztp, dvrfhvwgsi - cewxzgxgix) View more | ||||||
NCT02836548 (ESMO2022) Manual | Phase 1/2 | Melanoma BRAF V600 Mutation | NRAS Mutation | 25 | qoagjlbhft(gqklpchigg) = atldipqxqx exbksctvba (wwzrsgapfk ) View more | Negative | 10 Sep 2022 | |
Phase 2 | 42 | jrxkehdbpk(afxopoddit) = wvhapvstqq sjmbttveyz (rbcwuhfhrc ) | Negative | 23 Jun 2022 | |||
jrxkehdbpk(afxopoddit) = vypnlatbab sjmbttveyz (rbcwuhfhrc ) |